Johnson & Johnson reported second-quarter 2026 reported sales of $25.31 billion and net earnings of $5.534 billion, with diluted EPS of $2.27 and adjusted diluted EPS of $2.90. The company raised full-year 2026 guidance, increasing midpoint estimated reported sales to $101.1 billion and raising adjusted EPS midpoint to $11.68. Operational strength was driven by Innovative Medicine and MedTech contributions and multiple regulatory approvals and data readouts announced during the quarter.

Financial Highlights

  • Reported sales: $25,310 million in Q2 2026, up 6.6% versus Q2 2025 ($23,743 million).
  • Net earnings: $5,534 million in Q2 2026 (Q2 2025: $5,537 million).
  • Diluted EPS (reported): $2.27 for Q2 2026 (Q2 2025: $2.29).
  • Adjusted diluted EPS: $2.90 for Q2 2026 (Q2 2025: $2.77), representing a 4.7% increase year-over-year.
  • Raised full-year 2026 guidance: estimated reported sales midpoint $101.1 billion and adjusted EPS midpoint $11.68 (adjusted operational EPS midpoint $11.58).

Business Highlights

  • Operational sales growth: Worldwide operational sales up 5.6% year-over-year; adjusted operational sales growth 5.7% (excludes acquisitions/divestitures and translational currency).
  • Segment performance: Innovative Medicine operational sales grew 6.8%, driven by oncology brands (DARZALEX, CARVYKTI, TECVAYLI, RYBREVANT/LAZCLUZE), immunology (TREMFYA) and neuroscience (SPRAVATO, CAPLYTA); MedTech operational sales grew 3.6%, led by wound closure, biosurgery, electrophysiology, Shockwave and vision products.
  • Regional momentum: U.S. sales rose 7.3% to $14,533 million; International sales increased 5.7% to $10,777 million with 3.4% operational growth after currency effects.
  • Regulatory and product milestones: Multiple approvals and label expansions including TREMFYA for inhibition of joint damage in psoriatic arthritis, CAPLYTA for relapse prevention in schizophrenia, FDA approval for Dual Energy THERMOCOOL SMARTTOUCH SF platform, and CE mark for ETHICON 4000 stapler.
  • Clinical and pipeline progress: Positive data and advancements across oncology and immunology programs (RYBREVANT FASPRO in head & neck cancer; TALVEY plus DARZALEX FASPRO in multiple myeloma; IMAAVY data in gMG and wAIHA; multiple other late-stage and pivotal results announced).

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.